Botox-maker Allergan just picked up a regenerative medicine company for $2.9 billion
AP
The purchase is Allergan's first step into regenerative medicine, which it plans to apply to the plastic surgery space.
"The acquisition of LifeCell is both strategically and financially compelling to Allergan and serves as our entry point into regenerative medicine as we create a world-class aesthetic and regenerative medicine business in plastic surgery," Allergan CEO Brent Saunders said in a statement Tuesday.
Allergan was slightly down Tuesday morning on the news.
The deal closes out a year of deals for Botox-maker Allergan. In the month of September and beginning of October, Allergan committed $3.67 billion to acquisitions and investments, followed by more deals later in October and in November.
LifeCell's expected to generate $450 million in revenue in 2016, Allergan noted in a release. Its main products are tissue materials that are used in breast reconstruction and abdominal wall surgeries.
- US buys 81 Soviet-era combat aircraft from Russia's ally costing on average less than $20,000 each, report says
- 2 states where home prices are falling because there are too many houses and not enough buyers
- A couple accidentally shipped their cat in an Amazon return package. It arrived safely 6 days later, hundreds of miles away.
- India Inc marks slowest quarterly revenue growth in January-March 2024: Crisil
- Nothing Phone (2a) India-exclusive Blue Edition launched starting at ₹19,999
- SC refuses to plea seeking postponement of CA exams scheduled in May
- 10 exciting weekend getaways from Delhi within 300 km in 2024
- Foreign tourist arrivals in India will cross pre-pandemic level in 2024